

## Quality Statements for Melanoma Care in New Zealand | Consultation commencing soon

The updated 'Quality Statements for Melanoma Care in New Zealand' (formerly 'Standards of Service Provision for Melanoma Patients in New Zealand') are currently being externally peer reviewed by Professor John Thompson.

Keep an eye on your inbox - we will be seeking your feedback soon.

The Cancer Control Agency have been supporting the development and publication of the Quality Statements, however to ensure they are available to health professionals as soon as possible, MelNet will own the document and be responsible for updating it.

## **Auckland Skin Cancer Study Day for Nurses** | The role of a nurse in a skin cancer patient's journey

#### Friday 7 May 2021

#### Clinical Education Centre, Auckland City Hospital

For primary and secondary care nurses and nursing students, this study day will discuss skin cancer prevention, early detection, treatment and care, helping you to better understand the journey of a skin cancer patient and the critical role of a nurse throughout this journey. The cost of attending is \$75.00.

Spaces are limited and are filling up fast. Register now to avoid disappointment.

In the event Auckland is at COVID-19 Alert Level 2 at the time of the study day, attendee numbers will be restricted in line with COVID-19 regulations. Anyone who is registered but cannot be accommodated will be notified and refunded. No virtual option will be available.

See the programme More information

Kindly supported by









**Interested in learning more about dermatoscopy?** Skin Cancer Symposiums are generously offering study day registrants \$100 off their Certificate of Fundamental Dermatoscopy online course. <u>Find out more about the course</u> or <u>contact us</u> for more information.

## In the news | Sunscreen (Product Safety Standard) Bill to be debated in House

The Sunscreen (Product Safety Standard) Bill was recently drawn from the member's bills ballot. This bill would ensure sunscreens provide the protection they claim by making NZS 2604:2012 or any New Zealand Standard substituted for that standard mandatory. The Bill will have to pass three readings in the House before it becomes law and if passed, must be implemented no more than six months later.

Read the Sunscreen Product Safety Standard Bill

Calls for stronger sunscreen standards in NZ

Sunscreen safety set to become political issue after member's bill pulled from ballot

#### **Exciting research results** | Neoadjuvant therapy saving lives

A recent study has demonstrated that neoadjuvant therapy is effective in preventing the spread of melanoma. The study pooled data from six clinical trials where drug therapy was given before surgery.

Data suggests immunotherapy may work more effectively when given before, rather than after surgery. It also enables the clinician to assess the patient's response early and decide on an alternative plan if needed.

Read the research abstract

#### Recent releases from the Melanoma Institute of Australia

#### Podcast: "The complexities of adjuvant therapy in melanoma"

Listen to Medical Oncologist Associate Professor Alex Menzies discuss the evidence for adjuvant therapy to guide clinical decision-making.

#### Risk calculator: predicting disease spread in thin melanoma

Melanoma Institute of Australia have also released a risk calculator to help clinicians calculate the risk of a thin melanoma spreading.

Research underpinning this calculator is based on joint international collaboration between the Melanoma Institute of Australia and University Medical Center Utrecht in the Netherlands and was recently published in the Journal of Clinical Oncology.

Listen to the podcast

More information about the risk calculator

# **Upcoming opportunities and events**



# The science and practice of sustainable care for the self and others

27 - 28 March 2021

University of Auckland – Virtual option possible

Top scientific and clinical experts from New Zealand and overseas will discuss the importance of caring for the self in the helping professions and the links between self-care and the capacity to care for others.

More information Register now



28 - 30 May 2021 Gold Cost, Queensland

Hybrid event – in-person or virtual attendance available

Early bird registrations now open. This congress is for those who are passionate about skin cancer medicine, and want to know the latest in primary care diagnosis and treatment of skin lesions.

More information Register for in-person attendance Register for virtual attendance

#### **April**

#### **Certificate of Dermoscopy - Online**

2 April - 14 May 2021

Online event

**Further information** 

# Australasian College of Dermatologists 53rd Annual Scientific Meeting

9 - 11 April 2021

Online event

**Further information** 

#### **Certificate of Skin Cancer Medicine**

10 - 11 April 2021

Auckland

**Further information** 

#### **Certificate of Fundamental Dermatoscopy**

12 April 2021

Online event

**Further information** 

# 10th World Congress of Melanoma and 17th EADO Congress

15 - 17 April 2021

Online event

**Further information** 

## May

# ICMDD 2021: 15th International Conference on Melanoma Diagnosis and Dermatology

3 - 4 May 2021

Online

**Further information** 

# Royal Australasian College of Surgeons 2021 Annual Scientific Congress

10 - 14 May 2021

Hybrid (Melbourne, Australia and online)

**Further information** 

#### **Focus on Melanoma Regional Meeting**

14 May 2021

Online

**Further information** 

Professional Certificate of Skin Cancer Medicine Advanced Certificate of Skin Cancer Medicine Professional Certificate of Skin Cancer Surgery Advanced Certificate of Skin Cancer Surgery

Online and optional workshop in Perth on 15/16 May 2021

Further information

For more events see the MelNet events calendar

# **Recent MelNet website postings**

Below is a selection of recent news postings on the MelNet website. Please visit the <u>website</u> to view all the latest news items.

Whole-body MRI for the surveillance of melanoma patients is a safe and sensitive technique

Pembrolizumab safety and efficacy in the adjuvant setting for high-risk, resected melanoma

Careful monitoring and long-term follow-up are required for lentiginous melanoma

<u>Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III</u> <u>melanoma</u>

<u>Identification of preoperative peripheral inflammatory markers as indicators for poor prognosis in melanoma</u> patients with brain metastases undergoing neurosurgical treatment

<u>Development of LC3B as predictive biomarker of checkpoint inhibitor blockade for melanoma patients' responses</u> to immunotherapy

Strong dependence between tryptophan-related fluorescence of urine and malignant melanoma

Metformin is associated with decreased risk of basal cell carcinoma

Utrophin (UTRN) could serve as tumor suppressor and novel prognostic biomarker for melanoma patients

Interventions to improve histopathology agreement may reduce melanoma "over-calling" and "under-calling"





Support our work. Donate to MelNet